Harbour BioMed, a cancer therapies company has acquired Harbour Antibodies from Erasmus MC Holding, Atlas Holding and other shareholders. Harbour Antibodies focuses on the production of antibodies and VH (heavy chain with one variable) domains for therapy. With this acquisition, Harbour BioMed plans to expand its presence in the Boston area by establishing a drug discovery innovation centre.
VIOTTA advised Management and Workers on acquisition of Panteia B.V. from Stichting Panteia
VIOTTA advised Panteia B.V. with the acquisition by the management and Workers together with Nimbus Stichting Panteia. Panteia provides policy research & consultancy and market research services for small andVIEW CASE
When a bank’s termination of a bank account is unlawful
Banks have a duty of care to their customers. When terminating a credit relationship, the bank quite often forgets to comply with its duty of care. In this case, the interlocutory relief judge stopped Rabobank in its tracks. Rabobank was also ordered to reimburse the expenses of the injured party. Corporate lawyer Martijn Kesler explains.READ ARTICLE
Tokenization: converting assets into digital tokens
Tokenization thus offers the possibility to no longer physically transfer assets or rights, but to deliver them digitally via blockchain technology. The crypto financing lawyers of VIOTTA explain the possibilities surrounding tokens as follows.READ ARTICLE
The Material Adverse Change-clause: what is it and what’s it for?
The MAC clause is common in acquisition contracts and its purpose is to protect the buyer from circumstances that have a significant impact on the financial position of the target company.READ ARTICLE